None
Quote | Vivos (OTCMKTS:RDGL)
Last: | $0.17 |
---|---|
Change Percent: | -0.61% |
Open: | $0.166 |
Close: | $0.17 |
High: | $0.175 |
Low: | $0.1615 |
Volume: | 1,221,456 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Vivos (OTCMKTS:RDGL)
--News Direct-- By Meg Flippin, Benzinga In what could prove to be a transformational development in cancer treatment, Vivos (OTCQB: RDGL), the maker of the Radiogel™ Precision Radionuclide Therapy, submitted an application to the U.S. Food and Drug Administration (FDA) to init...
Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). The filing was an amendment, addressing the FDA comments to our previous application (Q211938/S001). Today’...
Message Board Posts | Vivos (OTCMKTS:RDGL)
Subject | By | Source | When |
---|---|---|---|
Rdgl is muito better than the bs on | Truthsocial | investorshub | 07/02/2024 7:01:11 PM |
Nobody is purchasing a company (that I know | rogers711 | investorshub | 07/02/2024 6:46:33 PM |
Its why I said a BO wouldnt happen | CatfishHunter | investorshub | 07/02/2024 6:41:20 PM |
Its why I said a BO wouldnt happen | CatfishHunter | investorshub | 07/02/2024 6:39:23 PM |
It seems buyouts have been for products/companies that | classics99 | investorshub | 07/02/2024 5:58:02 PM |
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- By Meg Flippin, Benzinga In what could prove to be a transformational development in cancer treatment, Vivos (OTCQB: RDGL), the maker of the Radiogel™ Precision Radionuclide Therapy, submitted an application to the U.S. Food and Drug Administration (FDA) to init...
Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). The filing was an amendment, addressing the FDA comments to our previous application (Q211938/S001). Today’...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...